Research Article
Volume 2 Issue 5 - 2016
Analgesic Effect of Ethanolic Extract of Bougainvillea X Buttiana (Var. Rose) Holttum & Standl
Rigoberto Villanueva Guerrero, Rodolfo Abarca-Vargas and Vera L. Petricevich*
Facultad de Medicina de la Universidad Autonoma del Estado de Morelos, Calle Iztaccihuatl Esq. Leñeros, Col. Volcanes, Cuernavaca, Morelos, Mexico
*Corresponding Author: Vera L. Petricevich, Facultad de Medicina de la Universidad Autónoma del Estado de Morelos, Calle Iztaccihuatl Esq. Leñeros, Col. Volcanes, Cuernavaca, Morelos, Mexico.
Received: December 09, 2016; Published: December 12, 2016
Citation: Vera L Petricevich., et al. “Analgesic Effect of Ethanolic Extract of Bougainvillea X Buttiana (Var. Rose) Holttum & Standl”. EC Pharmacology and Toxicology 2.5 (2016): 224-230.
Background: Bougainvillea sp is a medicinal plant traditionally used in Mexico to alleviate several diseases including painful disorders. The present study was carried out to evaluate the analgesic activity of ethanolic extracts of Bougainvillea x buttiana (var. Rose) Holttum & Standl.
Methods: Bougainvillea x buttiana bracts were extracted with ethanol. The extract was submitted to phytochemical qualitative analysis. The extract was orally administered at dose of 0.04, 0.4, 4 and 40 mg/kg. For analgesic evaluation were included methods for a peripheral mechanism pain such as the acetic-acid induced writhing method, and a central mechanism of pain as tail flick and formalin tests were used.
Results: The results obtained from the phytochemical qualitative analysis showed the presence of alkaloids, carbohydrates, fatty acids, lipids, saponins and tannins. Our results also clearly indicate that the oral administration of the Bougainvillea x buttiana extract caused a significant (p < 0.05) dose-dependent reduction in the number of abdominal writhes. The extract also produced a remarkable increase in tail immersion latency time and paw licking time.
Conclusion: The results obtained demonstrated that Bougainvillea x buttiana extract showed analgesic potential in all models of nociception implying that both peripheral and central pathways of analgesia are involved. This might be due to the presence of various classes of phytochemicals in the plan extract.
Keywords: Analgesic; Phytochemical; Ethanol Extract; Tail Immersion Test; Writing Test; Paw Licking
BxbREE: Ethanolic Extract of Bougainvillea x buttiana
According the International Association for the Study of Pain (IASP), the pain is defined as an unpleasant sensory or emotional experience associated with actual or potential tissue damage. This definition emphasizes the pain as a complex multidimensional sensory-perceptual phenomenon that represents a unique subjective individual experience [1]. Various studies have shown that the pharmacologic management of pain requires the use of analgesic drugs. These drugs are divided into two groups, opioid and non-opioid analgesics [2]. In the literature, different studies have shown the serious side effects such as: physical dependency, tolerance, addiction, gastrointestinal disorders [2,3]. The search for potent analgesic agents with minimal side effects remains the goal of many scientific studies [4]. Several natural products have been used in traditional medicine and the research of these products is guided by ethnopharmacological knowledge and that brings a substantial contribution to the innovation of drugs through new chemical structures or by the mechanisms of ac tion [5]. Bougainvillea is a genus of the Nyctaginacea family, has been widely used as a Mexican traditional medicine to treat respiratory infections, gastric ulcer, and stomach pain [6]. From the scientific point of view, in the last years several medicinal properties in extracts from Bougainvillea x buttiana (var. orange) have been reported including antinociceptive, anti-inflammatory and immunomodulation activities [6,7]. Extracts of Bougainvillea x buttiana of different colors also have antioxidant activity and differences in phenol content [8]. These differences observed for the ethanol extracts of B. x buttiana from different colors suggest a synergistic effect of the bioactive components, played an important role in the observed activities [8]. In this context, the objective of the present work was to investigate the antinociceptive activity of the ethanol extract of B. x buttiana (var. Rose-Cuernavaca).
Materials and Methods Chemicals and solvents
Ethanol, acetonitrile HPLC grade and standards (gallic acid), and carrageenan, were purchased from Sigma-Aldrich Chemical Co., (St. Louis, MO, USA). Standards such as Aspirin (Bayer Mexico, TOL, MEX). Dexamethasone (Generic, GDA, MEX).
Extraction of plant material
The flowers and bracts of Bougainvillea x buttiana were manually harvested in Cuernavaca, Morelos, Mexico, during summer 2015 and identified. A voucher specimen Bougainvillea x buttiana Holttum & Standl, was registered with the foil: 33870 for later reference and deposited at the Herbarium HUMO, CIByC (UAEM). The plant collection 110 g of flowers and bracts have been dehydrated at 25°C and grinded into powder were submerged in the ratio of 50/50 (w/v) for 3 days by continuous shaking. The extract was filtrated by using Whatman filter paper No 1, and the solvent was removed using a rotary evaporator at 50°C. The crude ethanolic extract of Bougainvillea x buttiana (var. Rose) was named as (BxbREE) and stored at -20°C for screening antinociceptive activity.
Phytochemical Screening
The phytochemical screening methods to detecting the compounds in ethanolic extract of Bougainvillea x buttiana were performed as per standard methods [9,10]. To detect the presence or absence of different constituents including: Dragendorff´s test for detecting alkaloids, Borntrager´s test for anthraquinone, Fehling´s test for carbohydrates, saponification for lipids, Foam test for saponins and Ferric chloride test for tannins.
The animals were purchased from Bioterio del Instituto Nacional de Salud Pu blica (Cuernavaca-Morelos, Me xico) BALB/c. female mice (20 - 25 g) were acclimatized to the laboratory for 1 week prior to the experiment. All the experimental animals had free access to water. The animals used for the experiments was made in accordance to the protocol approved by the Committee (CCUAL-FM-UAEM N. 002/2016).
Analgesic Activity
Mouse writhing assay
The animals were divided into 7 groups of 5 mice each. Writhing activity in mice was evaluated according the method described by Koster., et al. 1959 [11]. The different amounts of BxbREE were orally (v.o.) administered. One hour later, 100 μL of 0.6% acetic acid was administered intraperitoneally. The number of writhes/mice was counted during a period of 20 minutes, starting 10 minutes after the injection of acid acetic. Aspirin® and Dexamethasone 4 mg/kg and saline solution were used as standard and control, respectively, and were also intraperitoneally administered one hour before the acetic acid administration.
Tail Immersion Test
The tail immersion test was performed as described by Parimaladevi., et al. 2003 [12]. Experimental animals were randomly selected and separated into 7 groups of 5 mice each. The lower 4 cm portion of the tail was immersed in a 1 liter beaker of water maintained at 51 ± 1 °C. For all groups of control and experimental the reaction time (seconds) was chosen as the time when the animals completely withdrew their tails from hot water, a cut-off time of 10 seconds was allowed to avoid tissue damage. For control groups the animals were treated with saline solution. BxbREE extracts at doses of 0.04, 0.4, 4 and 40 mg/kg were orally administered at 1 hour before the assay. The standards Aspirin® and Dexamethasone were intraperitoneally administered with 4 mg/kg one hour before assay. The time of tail immersion was recorded at intervals of 0, 30, 60 and 120 minutes after administration.
Formalin Test
The formalin test was performed by using a method described by Hunskaar., et al. 1985 [13]. In brief: control groups were treated with saline solution. Groups of 5 mice were treated orally at 1 hour before the assay with different amounts of BxbREE extract. Groups of 5 mice were intraperitoneally treated with standards Aspirin® and/or dexamethasone (4 mg/kg). After 60 minutes, treatment for all tested drugs 20 μL of 1.0% formalin solution was given into the right hind paw of mice. After the different treatments, the animals were placed in separated boxes and licking/biting and flinching were recorded in two phases. The early phase (0 - 5 minutes) and the late phase (15 - 30 minutes) after formalin injection were evaluate.
Statistical Analyzes
The statistical significance of differences between the groups was obtained by the analysis of variance (ANOVA) test complemented by GraphPad Prism 6; p < 0.05 was considered significant.
Results and Discussion Phytochemical Screening
Qualitative analysis of ethanolic extract of BxbREE was performed for alkaloids, anthraquinones, carbohydrates, fatty acids, lipids, saponins and tannins. Table 1 shows the presence of the alkaloids, carbohydrates, fatty acids and tannins. The anthraquinones and saponins were absence in this sample.
Phytochemical Test Results
Alkaloids +++
Anthraquinone -
Carbohydrates +++
Fatty acids ++
Saponins -
Tannins +
Table 1: Qualitative analysis of ethanolic extract of BxbREE.
Absent (−), present (+), moderate (++), and abundant (+++)
Analgesic Activity
The analgesic drugs act on peripheral or central nervous system to selectively relieve pain without significantly altering consciousness [14]. Centrally acting analgesics act by raising the threshold for pain and, also altering the physiological response to pain. On the other hand, peripherally acting analgesics act by inhibiting the generation of impulses at chemoreceptor site of pain [2]. Three murine pain models, acetic acid-induced writhing, tail immersion test and formalin test, were employed in our study for screening of analgesic activity of Bougainvillea extract, all methods are useful. Administration of different amounts of ethanol extract of Bougainvillea x buttiana prior to acetic acid administration caused a dose-dependent reduction in the number of writhes compared to control (Figure 1). The greatest inhibition was observed at doses of 4 and 40 mg/kg. For these doses the number of writhes were similar those results observed in standard groups (Figure 1). The results of this study demonstrate that Bougainvillea x buttiana ethanolic extract possesses analgesic activity. Various studies have shown that the acetic acid-induced abdominal constriction is described to involve peripheral mechanisms. Like this, in peritoneal fluids the presence of acetic acid which can act indirectly by inducing the release of endogenous mediators such as prostaglandins, cyclooxygenase and lipooxygenase. The increase in prostaglandin levels within the peritoneal cavity then enhances inflammatory pain by increasing capillary permeability [15]. These products are capable to stimulate the nociceptive neurons sensitive to non-steroidal anti-inflammatory drugs [16]. The marked reduction of writhes number caused by the BxbREE suggests that its effect may be peripherally-mediated via the inhibition of synthesis of the inflammatory mediators.

Figure 1: Effect of BxbREE extract on acetic acid-induced mouse writhing. Groups of mice were orally administered with various amounts of BxbREE extract, other groups were orally administered with 4 mg/kg of Aspirin® and/or dexamethasone 60 minutes before of acetic acid administration, were used as described in Materials and Methods. Each bar corresponds to the results (mean ± SD) n = 5.

Tail Immersion Test
The tail immersion test is used for evaluating the centrally analgesic compounds [17]. This test consists of a thermal stimulus and increase in the reaction time is used for evaluating central antinociceptive activity [18]. The effects of the tested extract on tail immersion response in mice are presented in Figure 2. The antinociceptive extract caused a significant (p < 0.05), in a dose-dependent increase in the mean reaction time on tail immersion (Figure 2). The antinociceptive activity of Aspirin® and dexamethasone started at 15 minutes; however, the highest activity was observed at 30 minutes. Different dose of BxbREE extract displayed a significant activity in the tail immersion when compared with results obtained in control group (p < 0.05). In groups of mice treated with 0.04 and 0.4 mg/kg the maximum increase in tail immersion time was observed at 60 minutes after the treatment. For groups of mice treated with 4 and 40 mg/kg of BxbREE the maximum response was at 30 and 15 minutes, respectively (Figure 2). In 15th minute after treatment with 40 mg/kg of extract the tail immersion time was similar with those results obtained for groups treated with Aspirin®. The results obtained in this study suggested that the central antinociceptive property of the BxbREE extract was probably due to their anti-inflammatory activities.

Figure 2: Effect of BxbREE extract on time immersion tail. Groups of mice were orally administered with various amounts of BxbREE extract, other groups were orally administered with 4 mg/kg of Aspirin® and/or dexamethasone 60 minutes before of tail immersion, were used as described in Materials and Methods. Each bar corresponds to the results (mean ± SD) n = 5.

Formalin Test
Figure 3 shows the effect of BxbREE extract on formalin induced pain. There was significant dose-dependent reduction of time spent in licking and biting responses at both phases by the extract. At a 40 mg/kg of the extract used produced similar reductions in both phases when compared with those results obtained for Aspirin® group (Figure 3). The BxbREE extract inhibited both phases of formalin induced pain in mice. Formalin test is one of the most important analgesic models to correlate with clinical pain. The injection of formalin into plantar aponeurosis is able for induces biphasic nociceptive behavior in animals which seem to involve two distinctly different stimuli. In the early phase, formalin test pain occurs due to the direct stimulation of the sensory nerve fibers with the release of substance P and bradykinin. On the other hand, the late phase, is characterized by the releasing of compounds such as serotonin, histamine, bradykinin, and prostaglandins [19]. In this study show that the BxbREE was able cause significant inhibition of both phases in formalin test and suggests that it possesses central and peripheral analgesic activity.

Figure 3: Effect of BxbREE extract on time spent in licking and biting responses. Groups of mice were orally administered with various amounts of BxbREE extract, other groups were orally administered with 4 mg/kg of Aspirin® and/or dexamethasone 60 minutes before of formalin administration, were used as described in Materials and Methods. Each bar corresponds to the results (mean ± SD) n = 5.

The results obtained in this study indicate that the ethanolic extract of Bougainvillea x buttiana possesses potential analgesic activity which is mediated via central and peripheral mechanisms and confirmed its medicine use in the management of pain and inflammatory disorders.
This work was supported by Secretaria de Educacion Pública (SEP-PRODEP) – México and Consejo Nacional de Ciencia y Tecnología (CONACyT - México). The authors are grateful for the technical support of M. in C. Claudia García Alanis.
Conflict of Interest
The authors declare no conflicts of interest.
  1. Raj PP. “Pain Medicine: A Comprehensive Review. 2nd edition”. Texas: Mosby Inc (2003).
  2. Tripathi K.D. “Essential of medical pharmacology. 5th ed”. Jaypee Brothers Medical Publishers, New Delhi, India (2004).
  3. Hanson GR., et al. “Drugs and Society”.Jones and Bartlett, Boston, Mass, USA. 10th edition (2009).
  4. Mukherjere KP. “Quality control of herbal drugs: An approach to evaluation of botanicals”.(2000): 34.
  5. Rates SMK. "Plants as source of drugs”. Toxicon 39.5 (2001): 603-613.
  6. Alvarez Perez Gil A., et al. “Antiinflammatory and antinociceptive activities of the ethanolic extract of Bougainvillea xbuttiana". Journal of Ethanopharmacology 144.3 (2012): 712-719.
  7. Arteaga Figueroa L., et al. "Preliminary studies of the immunomodulator effect of the Bougainvillea xbuttiana extract in a mouse model”.Evidence-Based Complementary and Alternative Medicine article (2015).
  8. Arteaga Figueroa L., et al. “Antioxidant activity, total phenolic and flavonoid contents, and cytotoxicity evaluation of Bougainvillea xbuttiana”. International Journal of Pharmacy and Pharmaceutical Sciences 6.5 (2014): 497-502.
  9. Dominguez XA. “Me todos de Investigacio n Fitoquí mica”. Limusa, Mexico City, Mexico(1985).
  10. Brain KD and Turner TD. “The practical evaluation of phytopharmaceuticals. 2nd edn”. Wright Science Technica, Bristol (1975): 81-82.
  11. Koster R., et al. “Acetic acid for analgesic screening”. New Federation Proceeding 18 (1959): 412-416.
  12. Parimaladevi B., et al. “Studies on analgesic activity of Cleome viscosa in mice”. Fitoterapia 74.3 (2003): 262-266.
  13. Hunskaar S., et al. “A modified hot-plate test sensitive to mild analgesics”. Behavioural Brain Research 21.2 (1986): 101-108.
  14. Kulkarni S.K. “Handbook of Experimental Pharmacology”. 3rd rev. ed. New Delhi: Vallabh Prakashan (1999): 123-125.
  15. Zakaria ZA and Addul ZDF. "Antinociceptive, anti-inflammatory, and anti-pyretic properties of an aqueous extract of Dicranopteris linearis leaves in experimental animal models" Journal of Natural Medicines62.2 (2008): 179-187.
  16. Deraedt R., et al. “Release of prostaglandin E and F in an algogenic reaction and its inhibition”. European Journal of Pharmacology 61.1 (1980): 17-24.
  17. Benedicta Nkek-Chungag N., et al.“Analgesic and anti-inflammatory properties of Oxyanthus unilocularis”Journal of Medicinal Plants Research 4.10 (2010): 932-939.
  18. Carter RB. "Differentiating analgesic and non-analgesic drugs activities on rat hot plate, effect of behavioral endpoint”. Pain 47.2 (1991): 211-220.
  19. Tjsolen A., et al. “The Formalin test: an evaluation of the method”. Pain 51.1 (1992): 5-17.
Copyright: © 2016 Vera L Petricevich., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PubMed Indexed Article

EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005

EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777

EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347

EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478

EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253

EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033

EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992

EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505

EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793

EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211

EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047

EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560

EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318

EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819

EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840

EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344

EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476

EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658

EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489

EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278

EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108

EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571

EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333

EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883

EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001

EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937

EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723

EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726

EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603

EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646

EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616

EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290

EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226

EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812

EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268

News and Events

September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for October Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the November issue of respective journals. Submissions are accepted on/before October 07, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to